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OBJECTIVEdStudies have shown that patients without a consistent primary care provider
have inferior outcomes. However, little is known about the mechanisms for these effects. This
study aims to determine whether primary care physicians (PCPs) provide more frequent
medication intensiﬁcation, lifestyle counseling, and patient encounters than other providers in
the primary care setting.
RESEARCH DESIGN AND METHODSdThis retrospective cohort study included
584,587 encounters for 27,225 patients with diabetes and elevated A1C, blood pressure, and/
or LDL cholesterol monitored for at least 2 years. Encounters occurred at primary care practices
afﬁliated with two teaching hospitals in eastern Massachusetts.
RESULTSdOf the encounters documented, 83% were with PCPs, 13% were with covering
physicians, and 5% were with midlevel providers. In multivariable analysis, the odds of medi-
cation intensiﬁcation were 49% (P , 0.0001) and 26% (P , 0.0001) higher for PCPs than for
covering physicians and midlevel providers, respectively, whereas the odds of lifestyle counsel-
ing were 91% (P , 0.0001) and 21% (P = 0.0015) higher. During visits with acute complaints,
covering physicians were even less likely, by a further 52% (P , 0.0001), to intensify medica-
tions, and midlevel providers were even less likely, by a further 41% (P , 0.0001), to provide
lifestylecounseling.ComparedwithPCPs,thehazardratiosfortimeto thenextencounteraftera
visitwithoutacutecomplaintswere 1.11 forcoveringphysiciansand1.19for midlevelproviders
(P , 0.0001 for both).
CONCLUSIONSdPCPs provide better care through higher rates of medication intensiﬁca-
tion and lifestyle counseling. Covering physicians and midlevel providers may enable more
frequent encounters when PCP resources are constrained.
Diabetes Care 36:1147–1152, 2013
T
he disease burden from diabetes is
increasingintheU.S.andworldwide
(1,2). With this increased burden,
efﬁcient, quality care becomes even
more important.
Many studies have shown that pa-
tients who see multiple providers have
inferior outcomes (3–6). Continuity of
care has further been associated with
improved detection (7,8) and manage-
ment of hypertension (8), greater adher-
ence todiabetespreventivecareand other
guideline-consistent services (9–11), im-
proved medication adherence(12),better
glycemic control in patients with diabetes
(13,14), lower rates of hospitalizations
(15–17), and lower long-term mortality
(18).
Having multiple providers of primary
care was also associated with increased
medical services expenditures (17)
through increased ofﬁce visits, prescrip-
tions, and number of specialists seen for
disease-speciﬁc populations (19). Conti-
nuity of care was especially important to
patients who perceived their health as
poor (20), but the mechanisms for these
effects are not fully understood.
However, modern models of health
caredelivery,suchasthepatient-centered
medical home, emphasize a team-based
approach to patient care (21,22). These
teams will need to deliver effective care
even when the patient is not always seen
b yt h es a m ep r o v i d e r .U n d e rt h e s ec i r -
cumstances, it becomes critical to recog-
nize the beneﬁts and mechanisms of
continuity of care so they can be repli-
cated in the team setting.
Process measures tightly linked to
outcomes may be an effective way to
measure quality of care (23). During the
last decade, several process measures
tightly linked to patient outcomes in the
treatment of diabetes have been identiﬁed
(24), including medication intensiﬁcation,
lifestylecounseling(25),andencounterfre-
quency(25–28).Wethereforeconducteda
study to determine whether primary care
physicians (PCPs) perform better on these
measures of care than other providers.
RESEARCH DESIGN AND
METHODS
Design
We designed this retrospective cohort
study todetermineifPCPsaremorelikely
than covering providers to intensify med-
ications, provide lifestyle counseling, and
have shorter intervals to the next encoun-
ter for patients with diabetes and elevated
A1C, LDL, or blood pressure (BP).
Study cohort
Adultswithdiabetestreatedatprimarycare
practices afﬁliated with Brigham and
Women’s (BWH) and Massachusetts Gen-
eral (MGH) Hospitals for at least 2 years
between 1 January 2000 and 1 January
2010 were studied. Primary care practices
included internal medicine and family
practice specialties. All of the practices in
the study used Longitudinal Medical Re-
cord, an internally developed Ofﬁce of
the National Coordinator’s Authorized
Testing and Certiﬁcation Body–certiﬁed
electronic medical record (EMR) where all
patient care documentation, including
problem lists, electronic prescribing, and
provider notes, was recorded. Patients
were included in the study if they were at
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Epidemiology/Health Services Research
ORIGINAL ARTICLEleast 18 years old, had a documented diag-
nosis of diabetes or A1C $7.0%, and at
leastoneinstanceofA1C,BP,orLDLabove
treatment target. Patients with missing zip
codes were excluded to enable adjustment
for median household income byzip code.
We used treatment goals of ,7.0% for
A1C, ,100 mg/dL for LDL, and ,140/
90 mmHg for BP.
This study was approved by the Part-
ners HealthCare System institutional re-
view board, and the requirement for
written informed consent was waived.
Study measurements
An encounter with a health care provider
in a primary care practice served as the
unit of analysis. Encounters during un-
controlled periods were included in the
analysis. An uncontrolled period started
onthedaywhenA1C,BP,orLDLwasﬁrst
noted above the treatment target (27).
The period ended on the ﬁrst subsequent
date when all measures fell below the tar-
get. Encounters that fell within the un-
controlled period were included in the
analysis, whether or not measurements
were taken on that date.
The lowest measurement on a given
date was used in the analysis. Lowest BP
was deﬁned as the BP measurement with
the lowest mean arterial pressure. BP mea-
surements were only included in the en-
counter analysis if they were measured on
the same date as the encounter. If A1C and
LDLmeasurementswereunavailableonthe
encounterdate,themostrecentwascarried
forward if the measurement was within 6
months of the encounter date. Transient
elevationswere deﬁnedas isolated elevated
measurements that subsequently normal-
izedwithoutanymedicationintensiﬁcation
and were excluded from the analysis. Peri-
ods without any medication information
available in the EMR were excluded to
enable inclusion of insulin treatment as a
confoundervariableintheanalysis.Periods
thatcontainedmultipleencounterswithan
endocrinologist were excluded to focus the
analysis on the primary care setting where,
nationwide, most of diabetes care takes
place. Hyperglycemic and hyperlipidemic
periods in which rates of A1C and LDL
change, respectively, were greater than
three standard deviations from the mean
were excluded to eliminate likely measure-
menterrors.Finally,encounterswithatime
tothenextencounterexceeding1yearwere
excluded to ensure continuous receipt of
care at study practices.
AP C Pw a sd e ﬁned as the PCP with
whom the patient had the majority of
continuous encounters over a given in-
terval and could change in the course of
an uncontrolled period. A covering phy-
sician was any other physician in a pri-
mary care setting who treated a patient.
These physicianswereusuallyotherPCPs
in the same practice (similarly qualiﬁed
with respect to specialty and board certi-
ﬁcation)whowereassignedtourgentcare
or covering duty on a particular day.
Encounters with nurse practitioners and
physician assistants were assigned a mid-
level provider category.
We identiﬁed face-to-face encounters
based on availability of appropriate billing
codes; all notes without corresponding
billing codes were considered remote en-
counters. Acute encounters were deﬁned
by ICD-9 diagnosis codes for an acute
complaint (e.g., acute pain and/or infec-
tion) as previously described (29).
Documentation of lifestyle counseling
(diet, exercise, or weight loss) was compu-
tationallyabstractedfromthenotes,includ-
ing direct (eg, “strongly encouraged more
walking”)a n di n f e r r e d( e g ,“weight has
gone up”) instances of lifestyle counseling,
as previously described (27,30). We infer-
red lifestyle counseling if the subject was
referred to in a way that indicated it was
likely discussed with the patient (eg, not
simply weight recorded in the vital signs
s e c t i o n ) .W h e nc o m p a r e dw i t hh u m a n
double-entry, the software had a sensitivity
of between 91 and 97% and a speciﬁcity of
between 88 and 94%. Weight loss counsel-
ing was only considered for encounters
when a patient had a BMI $30 kg/m
2.
None of the practices studied during the
study period had a program that
encouraged a particular type of lifestyle
counseling or monitored lifestyle counsel-
ing delivered by providers.
Medication intensiﬁcation was deﬁned
as initiation of a new medication or an in-
creaseinthedoseofanexistingmedication
(29).
Demographic information, weight,
height, BP measurements, and medica-
tion and laboratory data were obtained
from the EMR at Partners HealthCare, an
integrated healthcare delivery network in
eastern Massachusetts that includes BWH
and MGH.
Figure 1dFlow chart shows selection of study patients.
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PCPs and quality of treatment of diabetesStatistical analysis
Summary statistics were constructed by
using frequencies and proportions for
categorical data and using means, stan-
dard deviations, medians, and ranges for
continuous variables.
The marginal Cox proportional haz-
ardsmodelforclustereddata(31)wasused
to estimate the association between pro-
vider type and time to next encounter,
and logistic regression models were used
to calculate the odds of medication inten-
siﬁcationandlifestylecounselingfordiffer-
ent provider types. All models were
adjusted for demographic confounders
(age,sex,race,primarylanguage,healthin-
surance, and median income by zip code),
aswellasthepatient’sCharlsonComorbid-
ityIndex(CCI)(32),treatmentwithinsulin
as a marker of severity of disease, presence
of obesity, diagnosis codes for metastatic
cancer within 1 year before the encounter
date; measurements of A1C, systolic and
diastolic BP, and LDL, face-to-face versus
remote encounters, acute complaints, hos-
pitalizationbeforethenextencounter(time
to next encounter analysis only), and an
interaction term between acute status and
providertype.Two-sidedPvalueswereob-
tainedusing typeIII testandwereadjusted
for multiple hypothesis testing using the
Simes-Hochberg method (33,34). All ana-
lyses were performed with SAS 9.3 soft-
ware (SAS Institute Inc., Cary, NC).
RESULTSdWeidentiﬁed33,559adults
with diabetes who experienced at least
one hyperglycemic, hypertensive, or
hyperlipidemic period and were regularly
seen in primary care practices associated
with BWH or MGH (Fig. 1). After exclud-
ing patients regularly treated by endo-
crinologists, without medication records,
only transient elevations in A1C, BP, and
LDL, likely A1C or LDL measurement
errors, and missing demographic infor-
mation, the remaining 27,225 unique
individuals with 584,587 primary care
encounters were included in the study.
Study patients did not have at least
onemeasureundercontroloverameanof
78% of total follow-up time (Table 1).
During the study period, patients’ mean
maximum A1C was 8.7%, BP was 157/90
mmHg, and LDL was 131 mg/dL. The
percentage of patients with measure-
ments available during the follow-up pe-
riod ranged from 92.9% of the time for
A1C to 99.9% of the time for BP.
During uncontrolled periods, 83% of
the encounters (Table 2) were with PCPs,
13% were with covering physicians, and
5% were with midlevel providers. Face-
to-face visits constituted 49% and acute
visits 19% of total encounters. PCP en-
counters constituted 84–85% of nonacute
and remote encounters but only 77% of
acute encounters. Covering physicians,
however, had a higher proportion (19%)
of acute encounters and 10–12% of non-
acute and remote encounters. Midlevel
providers consistently had 4–5% of acute,
nonacute, and remote encounters. During
all encounters, medication intensiﬁcation
occurred at 10% and lifestyle counseling
occurred at 40% of encounters, whereas
the mean time to the next encounter was
1.6 months. Mean times since last A1C
and LDL measurements were 9 and 10
weeks, respectively. Providers had access
to up-to-date A1C, BP, and LDL measures
at 64.0, 56.4, and 53.5% of encounters,
respectively.
In a multivariable logistic regression
model that controlled for patient demo-
g r a p h i c s ,C C I ,o b e s i t y ,A 1 C ,B P ,a n dL D L
measurements, metastatic cancer diagno-
sis, insulin status, and an interaction term
between acute encounter status and
provider type, the odds of medication
intensiﬁcation during nonacute encoun-
ters were 49% (P , 0.0001) and 26%
(P , 0.0001) higher for PCPs than for
covering physicians and midlevel provid-
ers, respectively (Table 3). Odds of life-
style counseling during nonacute
encounters were 91% (P , 0.0001)
higher for PCPs than covering physicians
and 21% (P = 0.0015) higher than mid-
level providers. During acute encounters,
covering physicians were less likely to in-
tensifymedicationsbyafurther52%(P,
0.0001), whereas midlevel providers
were less likely to provide lifestyle coun-
seling by a further 41% (P , 0.0001).
In a multivariable Cox proportional
hazards model that adjusted for demo-
graphics, CCI, insulin status, obesity,
metastatic cancer diagnosis, measure-
ments of A1C, systolic and diastolic BP,
and LDL, indicators for face-to-face and
acute visits, hospitalization before the
next encounter, and an interaction term
between acute status and provider type,
the hazard ratios for the time to the next
encounter after a visit without acute
complaints were 1.11 for covering physi-
cians and 1.19 for midlevel providers (P
, 0.0001 for both) compared with PCPs.
CONCLUSIONSdIn this large retro-
spective study, we have demonstrated
that PCPs were signiﬁcantly more likely
than other providers in the primary care
Table 1dPatient characteristics
Mean or count SD or percentage
Study patients, n 27,225
Follow-up time (months) 65.9 29.1
Time with elevated A1C, LDL, or BP (months) 48.7 33.9
Age (years)
1 59.6 14.0
Women, n 14,361 52.8
Race/ethnicity, n
White 18,338 67.4
Black 3,040 11.2
Hispanic 3,309 12.2
Other
2 2,538 9.2
English as the primary language, n 22,563 82.9
Health insurance, n
Private 11,404 41.9
Medicare 13,083 48.1
Medicaid 2,376 8.7
None/unknown 362 1.3
Median income by zip code ($1,000s) 53.3 20.8
A1C (% [% of patients with data]) 7.26 (91.9) 1.25
Systolic BP (mmHg [% of patients with data]) 129.6 (99.9) 10.8
Diastolic BP (mmHg) 74.7 6.9
LDL cholesterol (mg/dL [% of patients with data]) 100.0 (95.6) 27.2
CCI 5.4 4.5
BMI (kg/m
2 [% of patients with data]) 32.5 (66.3) 7.2
Continuous data are shown as the mean value, unless otherwise indicated.
1Age calculated at the start date of
the ﬁrst uncontrolled period.
2Includes unknown.
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Morrison and Associatessetting to provide lifestyle counseling and
medicationintensiﬁcationforpatientswith
uncontrolleddiabetes.Thisassociationwas
even stronger during visits in which the
patient had an acute complaint. These
results suggest that increased frequency of
lifestyle counseling and medication inten-
siﬁcation may be the mechanisms that
underlie better outcomes seen in patients
who have higher continuity of care.
Severalotherexplanationsfortheeffect
of continuity of care have been proposed:
increased time spent with one physician
improved the patient’s trust of his or her
physician (4), enhanced communication
between patient and physician, and in-
creased the physician’s knowledge of the
patient (10), but the evidence for their
directeffectonpatientoutcomesislimited.
Our study, however, describes mecha-
nisms that have been directly linked to
A1C, BP, and LDL control (25–28,35,36).
It is likely that multiple mechanisms con-
tribute to the effects of better disease out-
comes and that the importance of provider
type may vary by mechanism.
Many studies have shown that mid-
level providers can be more effective than
PCPs in treatment of chronic diseases
such as diabetes and hypertension
(37–40),particularlywithrespecttomed-
ication intensiﬁcation (41). The major
difference between our study and these
clinical trials is that the trials usually re-
quired midlevel providers to follow a
structured algorithm, whereas midlevel
providers in the practices we studied did
not follow any particular algorithm. This
current ﬁnding should be considered
when designing new practice models,
such as patient-centered medical homes.
Although PCPs are more effective than
midlevelprovidersandcoveringphysicians
in providing lifestyle counseling and in-
tensifying medication, a patient may be
seen more frequently in practices with
other providers available. This is corrobo-
ratedbytheshortertimetofollow-upvisits
after encounters with covering physicians
andmidlevelprovidersfoundinourstudy.
Therefore, practices with midlevel provid-
ers may provide more cost-efﬁcient care
because there are more opportunities for
medication intensiﬁcation and lifestyle
counseling at a lower cost, even if they are
not used as frequently. Midlevel providers
could, therefore, be especially helpful in
situations in which PCP resources are con-
strained, as they are almost universally
across the country (42–44).
These ﬁndings have several implica-
tions for clinical practice. First, they sug-
gest there should be less cross-covering
by other physicians. If patients must be
seen by a covering provider, better doc-
umentationofthePCP’streatmentplanin
the medical records may facilitate their
decision making and lower the threshold
for intervention. Finally, structured algo-
rithms for treatment of chronic disease
may be helpful in optimizing the care de-
livered by midlevel providers.
Lack of intervention for uncontrolled
diabetes by a covering provider who does
not know the patient well may be seen as
appropriate.However,itresultsinadditional
delay in treatment; in our study, the average
interval between encounters was at least 7
weeks. A proactive approach where the PCP
documents a speciﬁc plan of action could
improve coordination of care and allow
covering providers to take timely action, ac-
celerating achievement of diabetes control.
This study used natural language
processing technology that permitted
cost- and time-efﬁcient computational
analysis of thousands of patient encoun-
ters, including examination of hundreds
of thousands of narrative provider notes
in a matter of hours. In the future, similar
technologies could also be used to mon-
itor quality of patient care and/or supply
feedback to providers. This feedback
could help narrow the gap in care pro-
vided between PCPs and covering pro-
viders if feedback is used consistently.
Our study hada number of strengths.
The analysis focused on process-of-care
Table 2dEncounter characteristics
Variable Mean or count SD or percentage
Study encounters, N 584,587
Face-to-face visits, n 286,243 48.96
Acute visits, n 110,661 18.93
PCP encounters, n 483,890 82.77
Covering physician encounters, n 73,179 12.52
Midlevel encounters, n 27,518 4.71
Acute visits
With PCPs,
1 n 85,064 14.55
With covering providers, n 20,964 3.59
With midlevel providers, n 4,633 0.79
Nonacute visits
With PCPs, n 148,952 25.48
With covering providers, n 17,422 2.98
With midlevel providers, n 9,208 1.58
Remove visits
With PCPs, n 249,874 42.74
With covering providers, n 34,793 5.95
With midlevel providers, n 13,677 2.34
Encounters during which a patient is taking insulin, n 132,330 22.64
Encounters with a diagnosis of metastatic cancer
within the previous year,
2 n 15,787 2.70
Encounters during which patients are obese, n 302,270 51.71
Encounters with no next encounter, n 8,485 1.45
Encounters with an inpatient encounter before
next primary care encounter, n 17,131 2.93
Time to next encounter (days) 48.78 59.57
Encounters with lifestyle counseling, n 233,440 39.93
Encounters with medication intensiﬁcation, n 65,689 11.24
Time since last A1C measurement (days [% of
encounters with recent measurements]) 63.96 (64.0) 51.36
Time since last LDL measurement (days [% of
encounters with recent measurements]) 72.06 (53.5) 55.14
A1C measurements available within prior 6 months, n 374,097 63.99
BP measurements available on day of encounter, n 329,685 56.40
LDL measurements available within prior 6 months, n 312,632 53.48
Continuousdataareshownasthemeanvalue.
1Percentagesofencountersareoftotalencounters.
2Diagnoses
of metastatic cancer required two ICD-9 codes for the condition in the outpatient setting or one in the in-
patient setting.
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PCPs and quality of treatment of diabetesmeasures that are tightly linked to better
patient outcomes, allowing us to identify
likely mechanisms for the beneﬁcial ef-
fectsofcontinuityofcare.Thiswasalarge
study, conducted in an ethnically and
gender-diverse population, and thus is
likelytobegeneralizabletoothersettings.
Thisretrospectivecohortstudyalsohas
some limitations, beyond its inability to
establish causality. We did not use standard
performance measures to assess provider
performance. Instead, we focused on mea-
sures that have been shown to be tightly
linked to patient outcomes. We used the
CCI as a measure of the patients’ overall
disease burden in multivariable analyses.
The CCI was originally developed and val-
idated for hospitalized patients and may
thereforehaveskewedtheresults.However,
the CCI has also been shown to correlate
with mortality in multiple outpatient popu-
lations (45–47), and the conditions it in-
cludes have face validity as predictors of
mortalityinbothoutpatientsandinpatients.
Some of the data pertinent to the
analysis might have been missing; for
example, physicians may not have recor-
ded some of the BP measurements they
made. If missing data were distributed
unequally between different provider cat-
egories, it could have biased the study
ﬁndings. To minimize this effect, we used
BP information from structured EMR
records and also from narrative provider
notes (obtained using natural language
processing) where clinicians are more
likelytodocumenttheirownBPmeasure-
ments. We have previously shown that
this approach results in a more complete
datacollection(48).Physiciansalsomight
have been more likely to round the BP
measurements down if they were individ-
ually judged according to BP-based qual-
ity indicators. However, no quality
indicators were implemented at the in-
dividual provider level in the practices
studied during the study period.
Thestudywasconductedattwoteach-
ing hospitals in eastern Massachusetts. The
patients who seek care and the providers
who work in such networks may be differ-
ent from other populations. The practices
we studied did not have a large number of
midlevel providers, making it difﬁcult to
study the care they provide in more detail.
Furthermore, because no treatment algo-
rithms were in place in any of the practices
studied, midlevel providers who followed
an algorithm could not be compared with
those who did not.
We did not have information on the
patients’ health-related behaviors that
could have accounted for some of the ob-
served effects if they were distributed un-
equally between PCP versus non-PCP
encounters.
Finally,wewereunabletodistinguish
patients with type 1 diabetes from those
with type 2 diabetes. Because most of the
patients studied likely had type 2 diabe-
tes, our conclusions may not be applica-
ble to patients with type 1 diabetes.
In conclusion, this large, long-term
retrospective study showed that PCPs per-
form better on a number of critical process
measuresofdiabetescarethancoveringphy-
siciansormidlevelproviders.Theseﬁndings
suggest mechanisms for well-described im-
provements in quality of treatment seen
withhighercontinuityofcare.Theyshould
be taken into consideration in the design
andevaluationofnovelhealthcaredelivery
models, such as patient-centered medical
homes, and in quality improvement in
traditional care settings.
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